Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zastaprazan - Onconic Therapeutics

Drug Profile

Zastaprazan - Onconic Therapeutics

Alternative Names: JP-1366; OCN-101

Latest Information Update: 29 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jeil Pharmaceutical
  • Class Antiulcers; Azetidines; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Erosive oesophagitis
  • Phase II Gastro-oesophageal reflux

Most Recent Events

  • 14 Oct 2023 Efficacy and adverse events data from the phase III Zero-1 trial in Erosive oesophagitis presented at the 31st United European Gastroenterology Week (UEGW-2023)
  • 28 Jul 2023 Chemical structure information added
  • 07 Feb 2023 Onconic Therapeutics plans a phase I trial to assess food-effects on pharmacokinetics and pharmacodynamics of JP 1366 (In healthy adults) in South Korea in February 2023 (PO, tablet) (NCT05712681)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top